Neuvasq will participate in the Bio-Neuroscience Summit 2025 in Amsterdam, a dedicated forum for innovation, partnering and investment in central nervous system (CNS) research and development.
Emmanuel Lacroix (CEO) and Isabel Vogel (Business Alliance Manager) will connect and exchange about our programs that aims at restoring Blood-CNS barriers, leveraging Wnt surrogate antibodies in both neurology and ophthalmology.
Neuvasq’s lead programs focus on the development of engineered Wnt surrogate antibodies targeting Gpr124 and Reck, critical co-receptors in Wnt/β-catenin signaling.
Cookie policy